NEW DELHI, July 7 — More than 1.5 million new cancer cases are estimated annually in India, according to available data, and a large number of those are diagnosed late. The problem is structural. Current guideline-recommended cancer screening covers only a small fraction of cancer types.
That leaves many cancers undetected until they have already advanced to stages where treatment options narrow significantly. Strand Life Sciences, a diagnostics and research company, is working to change that calculus.
The company has developed a blood-based early detection technology that aims to detect multiple cancer types from a simple blood test. The approach relies on cell-free DNA analysis. This technique examines genetic material circulating in the bloodstream that has been shed by tumours.
By analysing these fragments, the test can potentially identify the presence of cancer before symptoms emerge.
The screening gap
The gap in current screening protocols is not a small one. Most guideline-recommended screening programmes worldwide cover only a handful of cancers — typically breast, cervical, and colorectal. For the dozens of other cancer types, there are no routine screening options.
This means patients often receive a diagnosis only after symptoms appear. By that point, the disease has frequently progressed to a stage where curative treatment becomes more difficult.
The potential shift that Strand Life Sciences is targeting is significant: moving diagnosis earlier in the disease trajectory, when treatment options are more effective and outcomes are generally better. The company stated that its technology is designed to address precisely this gap. A single blood draw, analysed for multiple cancer signals, could replace the current piecemeal approach.
Scale and supply chain
For a market the size of India, the implications are substantial. More than 1.5 million new cases annually means a large population that could benefit from earlier detection. The blood-based format is key to the technology’s potential for scale.
Unlike imaging-based screening, which requires expensive equipment and trained radiologists, a blood test can be processed through existing laboratory infrastructure. Strand Life Sciences has existing laboratory networks and experience in genomic analysis, according to the company’s public filings.
This existing infrastructure could support the deployment of the new test. The company has not disclosed specific timelines for regulatory approval or commercial launch. However, the filing indicates that the technology has moved beyond the research phase.
What to watch next
The key question is how quickly the technology can move from development to clinical deployment. Regulatory pathways in India for such diagnostic tests will determine the timeline. Another factor is cost.
For a blood-based screening test to achieve broad uptake in India, it must be priced affordably enough to reach the large population that currently has no screening options at all. Strand Life Sciences has not announced pricing details.
The company’s track record in genomic diagnostics suggests an awareness of the Indian market’s price sensitivity. If the technology delivers on its promise, it could represent a meaningful shift in how cancer is detected in India and potentially in other markets facing similar screening gaps. Consult your doctor for medical advice.
